.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Idiopathic Intracranial Hypertension Treatment Trial evaluated acetazolamide plus a low-sodium weight-reduction diet versus placebo plus diet in patients with idiopathic intracranial hypertension and mild visual loss. Acetazolamide produced a modest but statistically significant improvement in the primary visual-field outcome at six months, accompanied by improvements in papilledema and quality of life in the broader trial. The benefit is clinically meaningful because IIH can cause irreversible optic-nerve damage if raised intracranial pressure is not controlled. The trial also reinforces that weight reduction is an important component of management rather than an optional adjunct. For HCPs, treatment should be individualised according to visual function, papilledema severity, tolerability and the patient's ability to sustain weight loss. Acetazolamide can cause metabolic, gastrointestinal and renal adverse effects, so monitoring and dose titration are necessary. The evidence directly supports AIOC's neuro-ophthalmology focus on idiopathic intracranial hypertension and optic-nerve protection.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The Idiopathic Intracranial Hypertension Treatment Trial evaluated acetazolamide plus a low-sodium weight-reduction diet versus placebo plus diet in patients with idiopathic intracranial hypertension and mild visual loss. Acetazolamide produced a modest but statistically significant improvement in the primary visual-field outcome at six months, accompanied by improvements in papilledema and quality of life in the broader trial. The benefit is clinically meaningful because IIH can cause irreversible optic-nerve damage if raised intracranial pressure is not controlled. The trial also reinforces that weight reduction is an important component of management rather than an optional adjunct. For HCPs, treatment should be individualised according to visual function, papilledema severity, tolerability and the patient's ability to sustain weight loss. Acetazolamide can cause metabolic, gastrointestinal and renal adverse effects, so monitoring and dose titration are necessary. The evidence directly supports AIOC's neuro-ophthalmology focus on idiopathic intracranial hypertension and optic-nerve protection.
4 weeks back
Explore the therapeutic promise of TLR7 and TLR8 inhibitors in managing systemic lupus erythematosus and monogenic autoimmune diseases. Learn how targeting endolysosomal single-stranded RNA sensing and regulatory checkpoints like UNC93B1 and PLD4 offers precision treatment without broad immunosuppression.
Yesterday
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
Yesterday
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Yesterday
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Yesterday
